60 LabCorp's latest deal hones in on digital clinical trials for drug development
Mobi Health News
MAY 28, 2020
The company's drug development CRO, Covance, will integrate Medable's software to expand its decentralized trial capabilities
Drug Development Related Topics 
Clover Health launches drug development subsidiary
FierceHealthIT
JULY 11, 2019
Startup Medicare Advantage insurer Clover Health has launched a new drug development subsidiary called Clover Therapeutics.
Join
53,000+
INSIDERS
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
From start to finish, drug development could benefit from cloud computing
Mobi Health News
JULY 9, 2019
From streamlining operations to fine-tuning optimal treatments, the technology makes a business case for pharma
Clover Health's new subsidiary will rely on members, machine learning to fuel drug development
Mobi Health News
JULY 10, 2019
Dubbed Clover Therapeutics, the unit's first project will be a partnership with Genentech targeting ocular diseases among senior populations
Enriching RWE with Novel Data Sets: How Medical Imaging Data Can Accelerate Drug Development
hea!thcare innovation - Clinical IT
MAY 16, 2019
Real-world evidence has the potential to be especially valuable in a number of healthcare use cases
Health IT Leaders Expect To Make Broad Use Of AI and Machine Learning Technology
Healthcare IT Today
FEBRUARY 28, 2020
AI/Machine Learning Ambulatory Analytics/Big Data C-Suite Leadership Clinical Communication and Patient Experience EMR-EHR Health IT Company Healthcare IT Hospital - Health System IT Drug Development Healthcare AI Healthcare IT Today Survey Machine Learning Personalized Medicine Predictive Analytics Radiology AI Smart Exam Rooms Treatment Pathways Virtual Office Assistants
|
Questions prompt potential privacy expansion in interop rule
Morning eHealth
JANUARY 22, 2020
AI and drug developmentWhere’s the telehealth rule? —
#099: Dr. David Fajgenbaum on Chasing a Cure for Rare Disease
Digital Health Today
FEBRUARY 24, 2020
He’s also a pioneer in changing the way we go about developing drugs to treat people with rare diseases, and, in so doing, he’s managed to put his own condition into remission, and help many others as well. As an engineer and business leader, I've worked to develop, launch and scale innovative products and solutions that impact health and wellness. Podcast business of health drug development drug discovery rare diseases USA
How telemedicine is increasing diversity in clinical trials
KevinMD
MARCH 14, 2019
An important part of advancing medical research and drug development is making participation in clinical trials easier and more inclusive. To develop treatments that work on men, women, and children of all ages and different ethnicities we need to have clinical trial data that represents our diverse population.
The Impact of Agile In The Pharmaceutical Industry
Electronic Health Reporter
SEPTEMBER 17, 2020
As many know, the pharmaceutical industry is heavily regulated and specialized, with slow drug-development timelines, strict processes and quality requirements, and rigid silos. This article is copyrighted strictly for Electronic Health Reporter. Illegal copying is prohibited.
Ben-Gurion University introduces AI platform for monitoring and predicting ALS progression
Mobi Health News
FEBRUARY 19, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), today unveiled an artificial intelligence (AI) platform for monitoring and predicting the progression of neurodegenerative diseases for the purpose of identifying markers for personalised patient care and improved drug development
|
|
BenevolentAI gets $115M to harness AI for new drug discovery
Mobi Health News
APRIL 20, 2018
BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States. Existing backer Woodford Investment Management also participated in the round, which brings the company’s total funds raised to over $200 million
Cost of antibiotic-resistant infections in U.S. tops $2B per year
FierceHealthIT
MARCH 22, 2018
The study’s authors urge policymakers to support the development of new strategies to prevent infections and to support innovative antibiotic drug development A new study finds that antibiotic resistance adds more than $1,000 to the cost of treatment for a single patient. Multiply that by the estimated number of antibiotic-resistant infections, and costs run well over $2 billion per year.
Moving the Needle with Real World Data: How Oncology is Leading the Way
GNS Healthcare
AUGUST 1, 2019
The thought of gathering massive amounts of data, from claims to EHR to molecular and making it easily accessible for drug development research once seemed impossible, as did getting at previously 'undruggable' pathways that defied the effects of even the most innovative drugs. Now, with the advent of immuno-oncology, the oncology field is poised to take advantage of these advances to enable the development of precise therapies that match the right drug to the right patient.
Health Consumers Are Now Amazon-Primed for Healthcare – HealthConsuming Explains, Part 2
Health Populi
APRIL 29, 2019
As patients now assume the role of health consumer, they rationally expect retail-level experiences with greater first-dollar payment for health insurance, health care services and medical products like prescription drugs. In the past couple of months, Amazon announced many health-related plans and developments, including: Accepting medical and health savings accounts (HSAs) to pay for consumer health products like over-the-counter drugs.
MedTech’s Role in Fighting the Opioid Epidemic
Duane Boise
JANUARY 24, 2018
Of the 50,000 drug overdose deaths that occurred in 2015, roughly 33,000 of them were caused by opioids. One of the more widely accepted solutions to this epidemic is providing access to alternate forms of pain management, which is where MMJ BioScience’s innovative new FDA cannabis drug development comes into play. The current state of America’s opioid crisis is one of uncertainty and peril if we are to not make a change sooner than later.
COVID-19 has accelerated adoption of non-contact patient monitoring technology, says Frost & Sullivan analysis
Healthcare IT News - Telehealth
MAY 29, 2020
“These technologies can also be leveraged by pharmaceutical companies to monitor the results of the drugs developed by them," said Ashish Kaul, technical insights senior research analyst at Frost & Sullivan.
First Steps with Oracle Health Sciences Clinical One Cloud Service
Perficient
JUNE 22, 2020
The Clinical One platform enables data to be shared across phases and the various functions involved in drug development, as data can be entered once for use in multiple areas, including: Randomization and Supplies Management. A better, faster, more cost-effective way to bring drugs to market to the millions of patients who are waiting with hope.”. This will require us to transform our processes and how systems and departments interact throughout the drug development cycle.
The rise of mHealth and the convergence of medicine with AI and Big Data
Lloyd Price
FEBRUARY 20, 2020
Interestingly, the future of DTx may lie in cooperation rather than in competition with Big Pharma and drug development.
Coronavirus: Don’t Panic, Get Informed
American Well
JANUARY 29, 2020
For example, it’s unclear whether the disease can spread before a person develops symptoms or whether people who never become symptomatic can still spread the disease. Around the world, the newest coronavirus outbreak has millions of people concerned about their health.
Blockchain in Healthcare: A Vehicle Towards Digital Health 2.0?
The Digital Health Corner
MARCH 26, 2018
Blockchain was first developed as a means of transaction for the digital currency Bitcoin. Blockchain technology’s potential impact on the life sciences industry (drug development, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain. One can envision how blockchain might also stop drug counterfeiting thereby improving patient safety.
#091: Francesca Wuttke on Digital Transformation, Startups and Corporate Relationships
Digital Health Today
SEPTEMBER 6, 2019
Francesca is responsible for developing and executing an end-to-end company-wide digital transformation. Francesca has over 20 years of drug development and healthcare expertise in both the US and Europe, and most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund and previously held roles at Novartis and Mount Sinai school of medicine, just to name a few.
AI and Data Analytics to Combat Health Pandemic
New Age Healthcare
MAY 1, 2020
Countries such as India, Singapore, China, Korea, Spain and Israel have successfully developed and deployed indigenous mobile apps to provide instant notifications if an exposure to a covid infected person has occurred. Artificial Intelligence for Monitoring and Drug Development. AI and cloud computing are being used extensively to identify potential drugs and augment the research for coronavirus vaccine development.
Coronavirus: Don’t Panic, Get Informed
American Well
JANUARY 29, 2020
For example, it’s unclear whether the disease can spread before a person develops symptoms or whether people who never become symptomatic can still spread the disease. Around the world, the newest coronavirus outbreak has millions of people concerned about their health.
FDA Rejects SGLT Drug Zynquista for T1D Use
Insulin Nation
MARCH 24, 2019
The FDA declined to approve Zynquista a drug developed by Sanofi SA and Lexicon Pharmaceuticals intended for use with insulin in patients with Type 1 Diabetes. The generic name of the drug is sotagliflozin. The decision comes about two months after an FDA advisory panel divided over whether the once-daily oral drug should be approved as an add-on to insulin therapy. The post FDA Rejects SGLT Drug Zynquista for T1D Use appeared first on Insulin Nation.
Auxulin: Hyperglycemic Innovation Driven by Need
Insulin Nation
MAY 16, 2019
We spoke with Tommy Ritz, MBA, and Dr. Jason McDevitt, William & Mary’s Tech Transfer Director about Auxulin – [link] – the company they founded to market a new drug that alleviates hyperglycemic episodes. . patents to drugs in the development pipeline. The solution they found is a variation of a prescription drug that is off-patent and not widely used. Technically, this is a new use of an old drug,” McDevitt said. “We’re
Lilly Acquires Rights to Nasal Glucagon
Insulin Nation
OCTOBER 16, 2015
has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline. In October, FierceBiotech reported that the company pulled the plug on the development of evacetrapib, a drug meant to ward off heart attacks and strokes, after investing $90 million in costly clinical trials.
Leveraging T2D Drugs to improve T1D Therapy
Insulin Nation
NOVEMBER 27, 2018
In his studies, Type 1 diabetic patients have significantly benefited when their daily insulin regimen is supplemented with drugs developed to treat Type 2 diabetes. This was the first research ( release ) on using this Type 2 approved drug for T1D treatment and there were larger confirmatory studies ( release ) in 2016 and 2018. The study will supplement insulin therapy with these two drugs designed to treat Type 2 Diabetes or with semaglutide alone. “
Novartis CEO Is Going All in With Some Big Bets on R&D
Lloyd Price
NOVEMBER 21, 2018
In an interview with the Wall Street Journal, Narasimhan pointed to some of the investments the company has made into the cutting-edge areas of drug development, such as gene therapy and radiopharmaceuticals.
FemTech: The rise of Female Health innovation
Lloyd Price
JUNE 4, 2018
CVC’s recent acquisition of the women’s health division of the Israeli drug developer Teva for $800m created a company dedicated to contraception, fertility, menopause and osteoporosis. Silicon Valley Bank, Zinc.vc
Lilly Acquires Rights to Nasal Glucagon
Insulin Nation
OCTOBER 16, 2015
has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline. In October, FierceBiotech reported that the company pulled the plug on the development of evacetrapib, a drug meant to ward off heart attacks and strokes, after investing $90 million in costly clinical trials.
Digital Therapeutics: the keys to succeed!
Digital Health Today
AUGUST 7, 2019
The Digital Therapeutics Alliance developed a definition to differentiate DTx solutions from health and wellness apps. The ReSET Prescription Digital Therapeutic (PDT), developed in collaboration with Sandoz, treats patients with Substance Use Disorder (SUD). The second milestone was when Pear signed a collaboration deal with Novartis to co-develop digital therapeutics for schizophrenia and multiple sclerosis in March 2018.
What is Metformin?
Insulin Nation
OCTOBER 10, 2017
A drug prescription can come with a lot of questions. With our “Know Your Drugs” series, we provide you with a snapshot of the different diabetes drugs on the market, and links to additional information. Metformin is currently the most popular drug prescribed for those with Type 2 diabetes. It is considered a generally safe and effective drug for lowering blood sugar levels, and it’s one of the first diabetes medications prescribed after diagnosis.
How the 21st Century Cures Act Will Change Diabetes Care
Insulin Nation
DECEMBER 14, 2016
This legislation boosts funding to the National Institutes of Health and establishes an innovation grant fund to “accelerate the discovery, development, and delivery” of new treatments and therapies. New drug and device development has become so prohibitively expensive that few manufacturers can shoulder the development cost from idea to pivotal clinical trial or even raise the necessary capital in the financial markets.
Genomics Startup Human Longevity’s Valuation Falls 80% from $1.6 Billion down to $310M
Lloyd Price
DECEMBER 8, 2018
But key facets of its business didn’t develop as planned, say people familiar with the company. It had hoped to sell analytics to pharmaceutical companies as they increasingly incorporated genetic sequencing into drug development, these people say. Human Longevity Inc. raced to a billion-dollar plus valuation on the hopes that it could apply advances in genomics to improve medicine.
BCG Vaccine Shows Promising Signals of T1D Efficacy
Insulin Nation
FEBRUARY 7, 2019
We found in human and mouse research that defects in white blood cells causing disease had a signaling pathway that we could drug. We looked for generic drugs that stimulate TNF. The Bacillus Calmette–Guerin (BCG) vaccine is a microorganism developed as a vaccine for tuberculosis (TB) more than 100 years ago and has also been used as therapy for bladder cancer for the last 40 years. The Hygiene Hypothesis was developed in the UK in the 1960s.
Join us at the Global Clinical Trials Connect 2018, 25-26 April, London
mHealth Insight
APRIL 24, 2018
“The Global Clinical Trials Connect 2018 conference focuses on introducing pioneer technology, developing better patient engagement and collaborating strategies in clinical trials. The global pharmaceutical industry has seen a downturn in recent years because of the challenges and cost associated with pharmaceutical development, procrastination in drug development, etc. Aji Barot, Business Development Director, HealthUnlocked.
Lilly Acquires Rights to Nasal Glucagon
Insulin Nation
OCTOBER 16, 2015
has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline. In October, FierceBiotech reported that the company pulled the plug on the development of evacetrapib, a drug meant to ward off heart attacks and strokes, after investing $90 million in costly clinical trials.
New Blockchain ledger will let US residents sell personal Healthcare data
Lloyd Price
SEPTEMBER 9, 2018
Most people don't know it but there is a multi-billion dollar industry that collects healthcare information, strips it of basic personal identifiers such as name, address and Social Security Number, and then sells it off to researchers, drug developers, marketers and others.
FDA’s rejection of SGLT for T1D
Insulin Nation
JUNE 4, 2019
SGLT2 Development and Method of Action. Ever since the first SGLT2 inhibitor (dapagliflozin) was approved by the EU in 2011 and the USA in 2014, it and another nine gliflozin drugs developed since then have been considered for (off-label) use in Type-1 diabetes, as well as in Type-2 diabetes for which they were first approved. SGLT2 drugs provide these benefits with the modest downside of some potential urinary tract infection in women, all while reducing insulin need.
Let's personalize your content